| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.319.286 | 0 | 0 | 0 | 8.104.743 | - | - | - | - | - |
| Total Income - EUR | 1.319.293 | 0 | 0 | 0 | 8.143.919 | - | - | - | - | - |
| Total Expenses - EUR | 1.323.101 | 659 | 562 | 384 | 9.830.414 | - | - | - | - | - |
| Gross Profit/Loss - EUR | -3.808 | -659 | -562 | -384 | -1.686.495 | - | - | - | - | - |
| Net Profit/Loss - EUR | -3.808 | -659 | -562 | -384 | -1.687.936 | - | - | - | - | - |
| Employees | 1 | 1 | 0 | 0 | 66 | - | - | - | - | - |
Check the financial reports for the company - Pharmelix Trade S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 16 | 15 | 15 | 28.585 | - | - | - | - | - |
| Current Assets | 59.754 | 10.557 | 10.245 | 2.329 | 4.164.959 | - | - | - | - | - |
| Inventories | 29 | 28 | 28 | 27 | 271.616 | - | - | - | - | - |
| Receivables | 59.714 | 10.528 | 10.214 | 1.902 | 3.885.014 | - | - | - | - | - |
| Cash | 11 | 1 | 3 | 399 | 8.329 | - | - | - | - | - |
| Shareholders Funds | 11.436 | 10.661 | 9.918 | 2.363 | -1.685.242 | - | - | - | - | - |
| Social Capital | 47 | 47 | 46 | 45 | 421 | - | - | - | - | - |
| Debts | 48.317 | -88 | 342 | -19 | 5.885.213 | - | - | - | - | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Pharmelix Trade S.r.l.